CL2022002699A1 - Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. - Google Patents
Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton.Info
- Publication number
- CL2022002699A1 CL2022002699A1 CL2022002699A CL2022002699A CL2022002699A1 CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1 CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A CL2022002699 A CL 2022002699A CL 2022002699 A1 CL2022002699 A1 CL 2022002699A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- multiple sclerosis
- tyrosine kinase
- kinase inhibitor
- relapsing multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002699A1 true CL2022002699A1 (es) | 2023-03-31 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002699A CL2022002699A1 (es) | 2020-04-03 | 2022-09-30 | Métodos para tratar la esclerosis múltiple recidivante utilizando un inhibidor de la tirosina cinasa de bruton. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125906A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520469A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220163986A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115916205A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021249129B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019846A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177390A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022002699A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296990A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012310A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI907406B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202825A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI899163B (zh) * | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
| BR112023021235A2 (pt) | 2021-05-14 | 2023-12-12 | Loxo Oncology Inc | Formas cocristalinas de um inibidor da tirosina quinase de bruton |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| WO2024238524A1 (en) * | 2023-05-16 | 2024-11-21 | Genentech, Inc. | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| PL4049660T3 (pl) | 2016-02-29 | 2025-06-09 | F. Hoffmann-La Roche Ag | Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| EP3626239B1 (en) | 2017-05-18 | 2024-07-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Ezh2 inhibitor combined with btk inhibitor for treating tumor |
| US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| JP2022500408A (ja) * | 2018-09-12 | 2022-01-04 | デノボ バイオファーマ エルエルシー | エンザスタウリンとbtkの阻害剤との組合せおよびその使用 |
| EP3914250A1 (en) | 2019-01-22 | 2021-12-01 | F. Hoffmann-La Roche AG | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
| TWI899163B (zh) | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
-
2021
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 AU AU2021249129A patent/AU2021249129B2/en active Active
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022019846A2 (pt) | 2022-11-22 |
| TW202203925A (zh) | 2022-02-01 |
| IL296990A (en) | 2022-12-01 |
| AU2021249129B2 (en) | 2026-06-04 |
| JP2023520469A (ja) | 2023-05-17 |
| CN115916205A (zh) | 2023-04-04 |
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
| TWI907406B (zh) | 2025-12-11 |
| EP4125906A1 (en) | 2023-02-08 |
| AU2021249129A1 (en) | 2022-10-20 |
| WO2021202825A1 (en) | 2021-10-07 |
| CA3177390A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| MX2022012310A (es) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| UY39529A (es) | Nuevos agentes antivirales derivados de espiropirrolidina | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| MX2022012285A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BR112022014058A2 (pt) | Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms) | |
| UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| DE60215787D1 (de) | Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| ES2144119T3 (es) | Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada. | |
| BR112023025459A2 (pt) | Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos | |
| MX2024001540A (es) | Inhibidores para coronavirus. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| DE69332567D1 (de) | Inhibitoren von metazoan-parasit-proteasen | |
| BR112022007616A2 (pt) | Métodos e composições para tratar doença falciforme com um inibidor de ferroportina (vit-2763) | |
| CL2022002317A1 (es) | Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| MX2025003008A (es) | Regimen de dosificacion para el tratamiento de la pku con un inhibidor de la funcion de slc6a19 como piperidina | |
| ECSP22081150A (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica | |
| AR126166A1 (es) | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos | |
| AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
| BR0111158A (pt) | Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina |